German pharmaceutical company BioNTech has filed a lawsuit before the Federal Patent Court in a dispute with CureVac regarding Covid-19 vaccines, the court announced in Munich.
The case concerns a European patent from 2010 on messenger ribonucleic acid (mRNA) technology used in the production of the vaccine Comirnaty by BioNTech and its US partner Pfizer.
BioNTech is asking that the patent be declared invalid because the underlying idea is not new. According to the court, CureVac rejects this. There is no date for the trial yet.
Last summer, German biotech company CureVac filed a lawsuit against its competitor for patent infringement at the Dusseldorf Regional Court.
CureVac is demanding compensation for the infringement of a number of intellectual property rights from more than two decades of pioneering work in mRNA technology. The date for the trial has not been set.
CureVac founder Ingmar Hoerr is considered the discoverer of the new vaccination technology. Like the vaccines from BioNTech and Moderna of the US, it is based on so-called messenger RNA.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
